Source:http://linkedlifedata.com/resource/pubmed/id/11103934
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
47
|
| pubmed:dateCreated |
2000-12-4
|
| pubmed:abstractText |
p53-germline mutations located in the core DNA-binding domain have been associated with a more dominant tumor penetrance especially for breast cancer and brain tumors. We previously reported an unusual accumulation of CNS tumors associated with a unique p53 germline mutation, Y236delta (deletion of codon 236). To test whether this tissue-specific tumor predisposition reflects a gain-of-function activity of Y236delta, we generated transgenic mice expressing Y236delta in astrocytes using the regulatory elements of the glial fibrillary acidic protein (GFAP) gene. After transplacental exposure to N-ethyl-N-nitrosourea (25 mg/kg BW) brain tumors developed in 18% (7/39) of GFAP-Y236delta transgenic p53-/- mice, while in p53+/- mice the incidence was 28% (11/40) (P>0.3). However, the mean tumor latency for GFAP-Y236delta/p53+/- mice was significantly shorter than for p53+/- mice, with 19.9 weeks vs 31.6 weeks (P=0.039), respectively. Taken together, cell specific expression of Y236delta results in an acceleration of tumor progression but does not confer a higher tumor penetrance. Conceivably, the transdominant effect of Y236delta provided a growth advantage early in the progression of neoplastic cells, since the endogenous p53 wild-type allele was lost in all brain tumors independent of the genotype. This reflects well observations from human astrocytic neoplasms with p53 mutations.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0950-9232
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
9
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5329-37
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11103934-Animals,
pubmed-meshheading:11103934-Astrocytes,
pubmed-meshheading:11103934-Astrocytoma,
pubmed-meshheading:11103934-Brain Neoplasms,
pubmed-meshheading:11103934-Female,
pubmed-meshheading:11103934-Gene Expression,
pubmed-meshheading:11103934-Germ-Line Mutation,
pubmed-meshheading:11103934-Glioblastoma,
pubmed-meshheading:11103934-Glioma,
pubmed-meshheading:11103934-Humans,
pubmed-meshheading:11103934-Male,
pubmed-meshheading:11103934-Mice,
pubmed-meshheading:11103934-Mice, Inbred C57BL,
pubmed-meshheading:11103934-Mice, Inbred DBA,
pubmed-meshheading:11103934-Mice, Transgenic,
pubmed-meshheading:11103934-Microsatellite Repeats,
pubmed-meshheading:11103934-Neoplasm Invasiveness,
pubmed-meshheading:11103934-Telencephalon,
pubmed-meshheading:11103934-Tumor Suppressor Protein p53
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
|
| pubmed:affiliation |
Institute of Neuropathology, University Hospital of Zurich, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|